Calmodulin inhibitors modify cell surface changes triggered by a tumor promoter.
D000818:Animals; D002135:Calcium-Binding Proteins / Q000037:antagonists & inhibitors*; D002147:Calmodulin / Q000037:antagonists & inhibitors*; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects*; D002794:Choline / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000378:metabolism; D004817:Epidermis / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D008563:Membrane Lipids / Q000378:metabolism; D051379:Mice; D010704:Phorbols / Q000494:pharmacology*; D010743:Phospholipids / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D014268:Trifluoperazine / Q000494:pharmacology
D002135:Calcium-Binding Proteins; D002147:Calmodulin; D008563:Membrane Lipids; D010704:Phorbols; D010743:Phospholipids; D014268:Trifluoperazine; D004815:Epidermal Growth Factor; D002794:Choline; D013755:Tetradecanoylphorbol Acetate